Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Precigen, Inc. (NASDAQ:PGEN) has received a consensus rating of “Moderate Buy” from the five brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $6.33.

A number of research firms have weighed in on PGEN. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Precigen in a research report on Friday, November 15th. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th.

Precigen Stock Performance

Precigen stock opened at $1.11 on Monday. Precigen has a twelve month low of $0.65 and a twelve month high of $1.93. The stock has a 50 day moving average of $0.91 and a two-hundred day moving average of $1.06. The stock has a market capitalization of $325.08 million, a price-to-earnings ratio of -2.02 and a beta of 1.65.

Institutional Trading of Precigen

Several hedge funds have recently modified their holdings of the business. SG Americas Securities LLC lifted its holdings in shares of Precigen by 27.9% in the 4th quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 12,578 shares during the period. Exchange Traded Concepts LLC raised its holdings in Precigen by 10.2% during the third quarter. Exchange Traded Concepts LLC now owns 167,496 shares of the biotechnology company’s stock worth $159,000 after purchasing an additional 15,525 shares during the last quarter. Stifel Financial Corp raised its holdings in Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 15,680 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in Precigen by 40.7% during the second quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 16,486 shares during the last quarter. Finally, AQR Capital Management LLC raised its holdings in Precigen by 56.7% during the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 18,097 shares during the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.